MedTrace Logo

Dexrazoxane to Protect Against Hemorrhagic STEMI

NCT07502521 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-05-26

No results posted yet for this study

Summary

This Phase Ila trial evaluates whether the intravenous administration of Dexrazoxane can reduce permanent heart muscle damage in patients undergoing standard stent procedures (PCI) for a severe heart attack (STEMI).

Conditions

  • Acute Myocardial Infarction (AMI)

Interventions

DRUG

Dexrazoxane

Intravenous infusion administered adjunctively to primary PCI

DRUG

Normal Saline

Visually identical placebo infusion (Normal Saline 0.9% NaCl) of similar volume administered adjunctively to primary percutaneous coronary intervention (PCI). Administered at four timepoints: emergency room (pre-PCI), 4 hours, 8 hours, and 12 hours post-primary PCI, identical in appearance, volume, and schedule to the investigational product.

Sponsors & Collaborators

  • Rohan Dharmakumar

    lead OTHER

Principal Investigators

  • Keyur P Vora, MD MS FACC · Indiana University

  • Rohan Dharmakumar, PhD · Indiana University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-30
Primary Completion
2026-02-15
Completion
2026-03-16

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07502521 on ClinicalTrials.gov